Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232488 | 0.91 | SLC6A9 (0.56) | SLC6A9 | |
| SCHEMBL2896463 | 0.83 | SLC6A9 (0.68) | SLC6A9 | |
| SCHEMBL7887812 | 0.81 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL7886720 | 0.79 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL2571078 | 0.78 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL7895891 | 0.78 | SLC6A9 (0.62) | SLC6A9 | |
| SCHEMBL7887815 | 0.78 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL7887434 | 0.77 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL7894044 | 0.76 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL29242223 | 0.73 | NAMPT (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497289-B2 | 3.1.0 bicyclic GlyT1 inhibitors and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497289-B2 | 3.1.0 bicyclic GlyT1 inhibitors and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2013-07-30 | — | — | US | disclosed |
| US-20100256192-A1 | 3.1.0 BICYCLIC GLYT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2010-10-07 | — | — | US | disclosed |
| US-20100256192-A1 | 3.1.0 BICYCLIC GLYT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2010-10-07 | — | — | US | disclosed |
| WO-2010078348-A1 | 3.1.0 BICYCLIC GLYT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256192-A1 | 3.1.0 BICYCLIC GLYT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | SLC7A1, SLC5A1, SLC1A1 | SLC6A9 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.